Categories Health Care, LATEST

Where does Merck (MRK) stand in the cancer-drug race?

Shares of Merck and Co. (NYSE: MRK) this week pared some of their recent gains even as the ex-dividend date approaches. While most investors wouldn’t want to miss the opportunity, some may find the valuation too high. The pharma giant is scheduled to pay 61 cents in dividend next month, which justifies analysts’ buy rating on the stock with a price target that represents a 10% upside.

Popular cancer drug Keytruda continues to be the main growth driver for Merck, which accounted for about a quarter of its revenues in the last quarter. Recently, the FDA granted priority review for an additional indication of the drug, spurring a modest stock rally. With its close rivals facing generic competition, Keytruda might retain dominance in the oncology space going forward and play a bigger role in Merck’s top-line growth.

Merck’s (MRK) Q3 results beat estimates; sales boosted by oncology and vaccines

The good news is that unlike its peers who depend too much on their respective flagship products, Merck’s revenue sources go beyond Keytruda. What gives the company an edge is its prowess in the other areas of drug development, such as the vaccination lineup. Also, with a promising development pipeline in hand, Merck has more room for expansion.

Related: Retail space gets busy as firms see opportunity in healthcare

The stock had a slow start to the week despite the company announcing its decision to acquire biopharmaceutical company ArQule for about $2.7 billion, through one of its subsidiaries. Merck expects to boost its cancer portfolio by leveraging ArQule’s kinase inhibitor development program. The transaction is tentatively scheduled for closure in the first quarter.

In a similar deal, Sanofi (SNY) and Wall Street firm Synthorx on Monday entered into an agreement under which the French pharma company will acquire the latter for $2.5 billion, which is significantly higher than its current market value. The buyout is expected to give a fillip to Sanofi’s oncology portfolio.

For the third quarter, Merck reported a double-digit increase in earnings and revenues, aided by the continuing growth of the pharmaceutical segment. At $1.51 per share, adjusted earnings were up 27% year-over-year on revenues of $12.4 billion. Buoyed by the positive results, the management raised its full-year guidance.

Also see: Merck Q3 2019 Earnings Conference Call Transcript

Shares of Merck jumped to a nine-year high last week, continuing the steady uptick. The stock gained 17% since the beginning of the year and 7% in the past six months while witnessing significant volatility.

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

PG Earnings: Procter & Gamble Q3 profit climbs, beats estimates

Consumer goods behemoth The Procter & Gamble Company (NYSE: PG) announced financial results for the third quarter of 2024, reporting a double-digit growth in net profit. Sales rose modestly. Core

AXP Earnings: All you need to know about American Express’ Q1 2024 earnings results

American Express Company (NYSE: AXP) reported its first quarter 2024 earnings results today. Consolidated total revenues, net of interest expense, increased 11% year-over-year to $15.8 billion, driven mainly by higher

Netflix (NFLX) Q1 2024 profit tops expectations; adds 9.3Mln subscribers

Streaming giant Netflix, Inc. (NASDAQ: NFLX) Thursday reported a sharp increase in net profit for the first quarter of 2024. Revenues were up 15% year-over-year. Both numbers exceeded Wall Street's

Comments

  1. Pingback: Political Science
  2. Pingback: Career development
  3. Pingback: Graduate Studies
  4. Pingback: pannelli luci led
  5. Pingback: ring mma
  6. Pingback: mediprime
  7. Pingback: Fiverr Earn
  8. Pingback: Fiverr Earn
  9. Pingback: Fiverr Earn
  10. Pingback: Hooled luce led
  11. Pingback: fiverrearn.com
  12. Pingback: fiverrearn.com
  13. Pingback: fiverrearn.com
  14. Pingback: fiverrearn.com
  15. Pingback: redboost mediprime
  16. Pingback: Freight Broker
  17. Pingback: 3pl Broker
  18. Pingback: weather tomorrow
  19. Pingback: fiverrearn.com
  20. Pingback: fiverrearn.com
  21. Pingback: jute rugs
  22. Pingback: clima hoy ny
  23. Pingback: what is seo
  24. Pingback: frenchie puppies
  25. Pingback: FiverrEarn
  26. Pingback: FiverrEarn
  27. Pingback: future university
  28. Pingback: Lean
  29. Pingback: Warranty
  30. Pingback: Piano maintenance
  31. Pingback: FUE
  32. Pingback: FUE
  33. Pingback: FUE
  34. Pingback: FUE
  35. Pingback: Moving assistance
  36. Pingback: Classic Books 500
  37. Pingback: FiverrEarn
  38. Pingback: FiverrEarn
  39. Pingback: FiverrEarn
  40. Pingback: pupuk organik cair
  41. Pingback: Social Justice
  42. Pingback: french bulldog
  43. Pingback: live sex cams
  44. Pingback: FiverrEarn
  45. Pingback: FiverrEarn
  46. Pingback: FiverrEarn
  47. Pingback: FiverrEarn
  48. Pingback: FiverrEarn
  49. Pingback: FiverrEarn
  50. Pingback: FiverrEarn
  51. Pingback: pharmacy
  52. Pingback: solar
  53. Pingback: FiverrEarn
  54. Pingback: FiverrEarn
  55. Pingback: cheap sex cams
  56. Pingback: fullersears.com
  57. Pingback: fullersears.com
  58. Pingback: canine probiotics
  59. Pingback: live sex cams
  60. Pingback: frt trigger
  61. Pingback: 늑대닷컴
  62. Pingback: Free spin
  63. Pingback: superslot
  64. Pingback: allgame
  65. Pingback: 918kiss
  66. Pingback: หวย24
  67. Pingback: Face cleanser
  68. Pingback: pg slot
  69. Pingback: cybersécurité
  70. Pingback: megagame
  71. Pingback: evisa
  72. Pingback: 6mm arc ammo
  73. Pingback: poei informatique
  74. Pingback: Skywhip tanks
  75. Pingback: talktostrangers
  76. Pingback: text strangers
  77. Pingback: itsmasum.com
  78. Pingback: amsterdam jobs
  79. Pingback: losangeles jobs

Comments are closed.

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top